Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

This is a phase 2b, double-blind, placebo-controlled, 4-arm, adaptive-design trial, initially stratified by cisplatin regimen, and then randomized 1:1:1:1. The study will be conducted in subjects receiving ChemoRT for the treatment of squamous cell carcinomas (SCCs) of the oral cavity, oropharynx, hypopharynx, or larynx. The study includes a treatment period of approximately 7 weeks, depending on the subject's prescribed radiation plan, and Week 1 and Week 4 post RT follow-up visits. It also includes a longer follow-up period of approximately 12 months to determine if there is an effect of SCV 07 on the tumor response to ChemoRT.


Eligibility Criteria:
Inclusion Criteria:

* Willing and able to understand and sign an informed consent form (ICF) for the study approved by the Investigator's local or a central Institutional Review Board (IRB)
* Have recently diagnosed, pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx, or larynx that will be treated with ChemoRT as first-line treatment; subjects with a history of surgical management are eligible
* Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 50 and 72 Gy. Planned radiation treatment fields must include at least 2 oral sites (buccal mucosa, floor of oral cavity, tongue, or soft palate), with each site receiving ≥ 50 Gy
* Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2)
* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Have adequate hematopoietic, hepatic, and renal function at the screening visit:

  * Hematopoietic function

    * Hemoglobin ≥ 10 g/dL
    * Absolute neutrophil counts (ANC) ≥ 1,500 cells/mm3
    * Platelet count ≥ 100 × 109/L
  * Hepatic function

    * Total bilirubin \< 1.5 times the upper-normal limit (ULN)
    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 times the ULN
  * Renal function: Serum creatinine concentration ≤ 2 mg/dL; if result is ≥ 1.4 mg/dL and ≤ 2.0 mg/dL, a 24-hour urinary creatinine clearance test must be performed by the site's local laboratory. To be eligible for the study, a subject must demonstrate a 24-hour urinary creatinine clearance ≥ 50 mL/min
* Have a negative serum pregnancy test if a woman is of childbearing potential
* Agree to use medically acceptable methods of birth control during study participation and for 30 days following the last CTM treatment if a woman is of childbearing potential
* Males or females aged 18 years or older.

Exclusion Criteria:

* Tumor of the lips, sinuses, salivary glands, nasopharynx, or unknown primary tumor
* Metastatic disease (M1) Stage IV C
* Prior radiation to the head and neck
* Plan to be treated with cetuximab (Erbitux®)
* Have undergone induction CT
* History of other malignant tumors, excluding non-melanoma skin cancer or curatively excised in situ cervical carcinoma
* Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; anticipation of need for a major surgical procedure during the study
* Active infectious disease, excluding oral candidiasis
* Have OM at the baseline visit
* Have a diagnosis of autoimmune disease requiring chronic immunosuppression
* Known seropositivity for HIV, HBV, or HCV
* Prior use of SCV 07
* Have used any investigational agent within 30 days of randomization
* Are pregnant or breastfeeding
* Known allergies or intolerance to cisplatin
* Unable to give informed consent or comply with study requirements, including completing the subject diary and QOL instruments
* Have any other condition or therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with follow-up visits.